Advertisement

18F–FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer

  • Gary A. Ulaner
  • Raychel Castillo
  • Jonathan Wills
  • Mithat Gönen
  • Debra A. Goldman
Original Article

Abstract

Objectives

This study assesses 18F–FDG-PET/CT for patients with newly diagnosed estrogen receptor-positive/human epidermal growth factor receptor-negative (ER+/HER2-) and human epidermal growth factor receptor-positive (HER2+) breast cancer.

Methods

In this Institutional Review Board-approved retrospective study, our Healthcare Information System was screened for patients with ER+/HER2- and HER2+ breast cancer who underwent 18F–FDG-PET/CT prior to systemic or radiation therapy. The initial stage was determined from mammography, ultrasound, magnetic resonance imaging, and/or surgery.18F–FDG-PET/CT was evaluated to identify unsuspected extra-axillary regional nodal and distant metastases. The proportion of patients upstaged overall and stratified by stage and receptor phenotypes was calculated along with confidence intervals (CI).

Results

A total of 238 patients with ER+/HER2- and 245 patients with HER2+ who met inclusion criteria were evaluated. For patients with ER+/HER2-breast cancer, 18F–FDG-PET/CT revealed unsuspected distant metastases in 3/71 (4%) initial stage IIA, 13/95 (14%) stage IIB, and 15/57 (26%) stage III. For patients with HER2+ breast cancer, 18F–FDG-PET/CT revealed unsuspected distant metastases in 3/72 (4%) initial stage IIA, 13/93 (14%) stage IIB, and 13/59 (22%) stage III. The overall upstaging rate for IIB was 14% (95% confidence interval (CI): 9–20%).

Conclusions

18F–FDG-PET/CT revealed distant metastases in 14% (95% CI: 9–20%) of patients with stage IIB ER+/HER2- and HER2+ breast cancer, which is similar to upstaging rates previously seen in patients with stage IIB triple-negative breast cancer (15%, 95% CI: 9–24%). The detection of unsuspected distant metastases in these patients alters treatment and prognosis. NCCN guidelines should consider adding patients with stage IIB breast cancer for consideration of systemic staging with 18F–FDG-PET/CT at the time of initial diagnosis.

Keywords

Estrogen receptor Human epidermal growth factor receptor 2 Breast cancer 18F–FDGPET/CT 

Notes

Compliance with ethical standards

Funding

This work was supported by a Susan G. Komen for the Cure Research Grant KG110441 (GAU), as well as the MSKCC Biostatistics Core (P30 CA008748).

Conflict of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was waived by the institutional review board for this retrospective study.

References

  1. 1.
    Groheux D, Espie M, Giacchetti S, Hindie E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388–405.CrossRefPubMedGoogle Scholar
  2. 2.
    Gilardi L, Fumagalli L, Paganelli G. Preoperative PET/CT in early-stage breast cancer: is the TNM classification enough? Ann Oncol. 2013;24:852.CrossRefPubMedGoogle Scholar
  3. 3.
    Bernsdorf M. Reply to ‘preoperative PET/CT in early-stage breast cancer: is the TNM classification enough?’. Ann Oncol. 2013;24:852–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Groheux D, Hindie E. Breast cancer staging: to which women should 18F-FDG PET/CT be offered? J Nucl Med. 2015;56:1293.CrossRefPubMedGoogle Scholar
  5. 5.
    Ulaner GA, Riedl CC. Reply: breast cancer staging: to which women should 18F-FDG PET/CT be offered? J Nucl Med. 2015;56:1293–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:324–54.CrossRefGoogle Scholar
  7. 7.
    Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gonen M, Osborne JR, et al. Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med. 2015;56:1674–80.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dashevsky BZ, Goldman DA, Parsons M, Gonen M, Corben AD, Jochelson MS, et al. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging. 2015;42:1666–73.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208:341–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003;12:247–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55:1578–83.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.CrossRefPubMedGoogle Scholar
  13. 13.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506–19.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.CrossRefPubMedGoogle Scholar
  18. 18.
    Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013;57:312–21.PubMedGoogle Scholar
  19. 19.
    Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–68.CrossRefPubMedGoogle Scholar
  20. 20.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national Comprehensive cancer Network. Cancer. 2012;118:5463–72.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205–14.CrossRefPubMedGoogle Scholar
  25. 25.
    Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1937–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Edge S, Byrd D, Compton C. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  27. 27.
    Groheux D, Hindie E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–87.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    King TA, Lyman JP, Gonen M. TBCRC 013: a prospective analysis of the role of surgery in stage IV breast cancer. Poster presented at: 2013 San Antonio Breast Cancer Symposium; December 10–14, 2013; San Antonio, TX. Abstract P2–18–09.Google Scholar
  29. 29.
    Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16:1111–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology. 2004;230:417–22.CrossRefPubMedGoogle Scholar
  31. 31.
    Sebro R, Aparici CM, Pampaloni MH. Frequency and clinical implications of incidental new primary cancers detected on true whole-body 18F-FDG PET/CT studies. Nucl Med Commun. 2013;34:333–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of RadiologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of RadiologyWeill Cornell Medical CollegeNew YorkUSA
  3. 3.Department of Information SystemsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations